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Abstract Elf-1 is a lymphoid-specific transcription factor that 
belongs to the ETS protein family. It can bind to DNA target 
sequences within a variety of cytokine genes. We demonstrate 
that Elf-1 is constitutively localized in the nucleus which is 
dependent on the presence of amino acids 86-265. Analysis of 
Gal4-Elf-1 fusion proteins revealed that the N-terminal 86 amino 
acids of Elf-1 contain a transcriptional activation domain, the 
activity of which is attenuated by an internal repression domain. 
Furthermore, Elf-1 interacts specifically with the E74 target 
sequence and can stimulate transcription driven by the E74 site 
independent of mitogenic signaling. Thus, Elf-1 is able to 
stimulate gene transcription which may be required for the 
development and activity of lymphocytes. 
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scription factor complex which mediates the cyclosporine A-
sensitive activation of the IL-2 gene [12], because Elf-1 could 
potentially bind within the NF-AT site of the IL-2 promoter. 
However, cloning of NF-A T genes revealed that NF-AT does 
not contain Elf-1 nor does NF-AT require any ETS protein to 
bind to a site with a GGAA core sequence [19,20]. Further-
more, Elf-1 binds with high affinity to the immunoglobulin 
heavy-chain enhancer pi site [21] and to the promoters of the 
tyrosine kinase encoding genes blk and lyn [22] and may thus 
contribute to the proper function of B-cells. 
In this report we demonstrate that the Elf-1 protein is con-
stitutively localized within the cell nucleus. Also, we identify 
an N-terminal activation domain as well as a central negative 
regulatory domain and show that Elf-1 mediates transcription 
from the E74 binding site independent of extracellular signals 
funneling through mitogen-activated protein kinases 
(MAPK). 
1. Introduction 
The DNA binding protein Elf-1 is a member of the ETS 
protein family which is involved in developmental processes 
[1,2], mitogenic activation of cells [3], oncogenesis [4,5] and 
viral gene activation [6,7]. All ETS proteins require a GGAA/T 
core sequence for specific DNA binding whereby flanking nu-
cleotides determine the specificity and affinity of a single ETS 
protein towards a particular binding site [8,9]. Since almost 
always several ETS proteins can potentially bind to a given 
target sequence, preferential binding of a unique ETS protein 
can be achieved by selective interaction with another tran-
scription factor bound to a flanking DNA sequence, or by 
tissue-specific expression [10]. Furthermore, the activity of 
some ETS proteins can be regulated at the level of phosphor-
ylation as was shown, for example, for the ETS proteins Ets-
1, Ets-2, Elk-1 and Sap-la [3,11]. 
Elf-1 was described as a lymphoid-specific ETS protein [12] 
that can bind autonomously to different promoter sequences 
of lymphoid-specifically expressed genes, including those en-
coding interleukin-3 [13], granulocyte-macrophage colony-
stimulating factor [14], CD4 [15] and interleukin-2 (IL-2) re-
ceptor a [16], as well as to the long terminal repeats of T-cell 
trophic viruses like HIV-2 [17] and HTLV-I [18]. Elf-1 had 
also been suggested to be a component of the NF-AT tran-
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2. Experimental procedures 
2.1. DNA cloning 
Segments of Elf-1 cDNA were cloned into the pABGal-linker plas-
mid to generate eukaryotic expression vectors for the different Gal4-
fusions or into a CMV enhancer/promoter-driven mammalian expres-
sion vector providing a hemagglutinin (HA) tag [23]. The luciferase 
reporter gene constructs tk80-luc, E743-tk80-luc and Gal42-tk80-luc 
have been described before [24]. 
2.2. Expression of proteins 
Rabbit kidney epithelial-like cells (RK13) were cultured in 
RPMI+10% FCS. 30 μg plasmid DNA were used to transfect 50%-
confluent RK13 cells on a 10 cm dish using the calcium-phosphate 
coprecipitation method. After an incubation period of 8 h the cells 
were rinsed twice in 10 mM Hepes, pH 7.3, 142 mM NaCl, 6.7 mM 
KC1 and grown for additional 12-18 h in RPMI+10% FCS. Then, the 
cells were washed with PBS and were taken off the dish with 40 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM EDTA. After centrifugation 
(3 min, lOOOXg) the cell pellet was taken up for lysis in 0.5 ml of 50 
mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 10 mM NaF, 
0.5% Triton X-100, 0.05% sodium deoxycholate, 1 mM DTT, 0.5 mM 
PMSF. After 20 min on ice cell debris was removed by centrifugation 
(10 min, lOOOOXg) and the protein extract was frozen in liquid nitro-
gen and kept at -80°C. 
2.3. Luciferase assays 
RK13 cells were transiently transfected and lysed 36 h post-trans-
fection [24]. The cell lysate was used to measure the luciferase activity 
in a buffer containing 25 mM glycylglycine, 15 mM MgSC>4, 5 mM 
ATP and 0.1 mM D-luciferin (AppliChem). As a control for trans-
fection efficiency, a β-galactosidase expression vector was always co-
transfected and ß-galactosidase activity was determined by incubating 
50 μΐ cell lysate with 1 mg/ml o-nitrophenyl ß-D-galactopyranoside 
(AppliChem) in 60 mM Na2HP04, 39 mM NaH2P04, 10 mM 
MgS04, 2 mM DTT. The generated o-nitrophenolate was measured 
at 405 nm in a spectrophotometer. 
2.4. Immunofluorescence studies 
HeLa cells growing on cover-slips were transfected using the calci-
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um phosphate coprecipitation method [24]. After 24 h the cells were 
washed twice with PBS before fixing them for 6 min in methanol at 
—20°C. The cells were washed 3 times with PBS and incubated for 20 
min with PBS/1% bovine serum albumin prior to a 1 h incubation 
with a murine monoclonal antibody against the HA epitope [23]. 
After a further washing of the cells an incubation with goat a-mouse 
antibodies coupled with fluorescein isothiocyanate was performed. 
The cells were washed twice with PBS, once in PBS containing 1 μg/ 
ml Hoechst dye 33258, twice with PBS and once with water. After 
mounting on a slide with Entellan (Merck), indirect immunofluores-
cence microscopy was performed with a 100 X lens and a 10 X ocular. 
2.5. Gel retardation assay 
Protein extract (2 μ)1 was incubated with 0.1 μΐ of 32P-labeled oli-
gonucleotide (0.5-1 ng) and 8 μΐ of 10 mM Tris-HCl, pH 7.5, 50 mM 
NaCl, 1 mM EDTA, 0.05% non-fat dry milk, 5% glycerol, 0.1 μg/μl 
poly(dldC)(dldC), 10 mM DTT. The reaction was performed for 30 
min at room temperature. Before electrophoresis on a 5% acrylamide 
gel (0.5XTBE) 2 μΐ of 10% Ficoll 400, 15% glycerol, 40 mM EDTA 
were added to the binding reactions. After electrophoresis at room 
temperature the gel was dried and exposed to an X-ray film for 12 h. 
The sequence of the E74-oligonucleotide was (asterisks highlight gua-
nine residues mutated to cytosine in the mE74-oligonucleotide): 5'-
AGCTTCTCTAGCTGAATAACCG*G*AAGTAACTCATCGTCG-
A-3'. 
3. Results 
3.1. Intracellular localization of Elf-1 
Several ETS proteins have been proven to stimulate, or 
even repress, gene transcription [3,8,9]. By necessity, a tran-
scription factor has to act in the nucleus. But some transcrip-
tion factors reside in the cytoplasm and require signal-induced 
translocation from the cytoplasm to the nucleus like NF-AT 
[25]. In order to investigate the intracellular localization of 
Elf-1 and map its nuclear translocation region by indirect 
immunofluorescence microscopy, HeLa cells were transiently 
transfected with Elf-1 expression vectors. Since all expressed 
Elf-1 proteins possessed an N-terminal HA-tag, a monoclonal 
antibody directed against the HA-tag was employed for de-
tection. 
As a control, we stained HeLa cells transfected with the 
empty expression vector (pEVRF2-HA) which gives rise to a 
short pep tide containing the HA-epitope. As demonstrated 
before [26], this peptide was localized within the cytoplasm 
(Fig. 1). Analysis of the full-length Elf-1 protein (1-619) 
showed that it was exclusively localized within the cell nucleus 
(Fig. 1). An identical result was obtained with untagged Elf-1 
stained with an antibody directed against the C-terminal 19 
amino acids (data not shown). Similarly, the C-terminal trun-
cations Elfi-485 and Elfl-265 gave a nuclear staining, whereas 
a whole-cell staining was unexpectedly observed with Elfl-
303. Deletion of the N-terminal 85 amino acids did not affect 
the nuclear localization, as shown with E1Í86-619 and Elf86-
285. Interestingly, the staining pattern of Elfi-485 revealed an 
uneven distribution of this protein in the nucleus which was 
reproducibly observed. 
The presented data were obtained with continuously grow-
ing HeLa cells cultivated in medium containing 10% fetal calf 
serum. We have also analysed serum-starved HeLa cells be-
fore or after mitogenic induction with phorbol-ester, but no 
difference in the staining pattern of Elf-1 was noticeable (data 
not shown). We therefore conclude that Elf-1 is a constitutive 
nuclear protein. 
3.2. Mapping of a transactivation domain 
To study the transcriptional potential of Elf-1, we fused 
parts of Elf-1 to the DNA binding-domain of the yeast pro-
tein Gal4 (Fig. 2). A Western blot revealed that all Gal4-Elf-1 
fusion proteins were expressed to comparable levels (not 
shown). Then, these fusion proteins were tested with a report-
er construct driven by two Gal4 binding sites. While the Gal4 
moiety itself was transcriptionally inert (see Gal4 in Fig. 2), 
the Gal4-Elf-1 fusion (G/El-619) raised the relative luciferase 
activity by a factor of 10. This effect was binding-site specific, 
since a luciferase reporter devoid of the Gal4 binding-sites 
(tk80-luc) was not responsive to G/El-619 (Fig. 2, right pan-
el). Thus, Elf-1 has the potential to activate transcription. 
Deletion of C-terminal amino acids down to position 265 
did not alter the transactivation potential, as demonstrated 
with the G/El-485, G/El-303 and G/El-265 fusion proteins 
(Fig. 2). Surprisingly, further deleting amino acids from the C-
terminus raised transcriptional levels with the G/El-205, G/ 
El-104 and G/El-86 constructs, indicating that amino acids 
206-265 may contain an inhibitory domain. Furthermore, de-
letion of the first 85 amino acids resulted in transcriptionally 
inactive proteins (see G/E86-265 and G/E86-202). Altogether, 
these results suggest that the N-terminal 86 amino acids of 
Elf-1 encompass a transactivation domain and that amino 
acids 206-265 attenuate the transactivation potential of the 
N-terminal activation domain. 
Fig. 1. The nuclear localization of Elf-1 was assayed by indirect im-
munofluorescence microscopy. HeLa cells were transiently trans-
fected with full-length HA-tagged Elf-1 (1-619), respective trunca-
tions or the empty expression vector pEVRF2-HA and subsequently 
stained with a monoclonal antibody directed against the HA-epit-
ope. 
3.3. E74 site dependent transcription mediated by Elf-1 
The ETS domain of Elf-1 is highly homologous to that of 
the Drosophila E74 protein, which resulted in the name E74-
like-factor [12], although otherwise the two proteins are differ-
ent. Thus, we tested whether Elf-1 could bind to the E74 
target sequence. As shown in a gel retardation assay (Fig. 3) 
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Fig. 2. Mapping of the Elf-1 transactivation domain. Transcriptional analysis of the depicted Gal4-Elf-1 fusion proteins was measured in RK13 
cells using a Gal4 binding site-driven luciferase reporter construct (Gal42-tk80-luc) or a reporter construct devoid of the Gal4 binding site 
(tk80-luc). 
Elf-1 can bind to the E74 target sequence. In order to assess 
the specificity of this DNA binding, competition experiments 
with unlabeled oligonucleotides were performed. While a 100-
fold molar excess of unlabeled E74-oligonucleotide completely 
abolished Elf-1 interaction with the 32P-labeled E74-oligonu-
cleotide (Fig. 3), no effect was observable with the mE74-oli-
gonucleotide in which the GGAA core sequence of the E74 
binding site was changed to CCAA. Similarly, a different ETS 
binding site (GABP), to which the GABP protein complex 
binds with high affinity [8,9], was incapable to compete with 
the 32P-labeled E74-oligonucleotide for binding to Elf-1. 
These results indicate that Elf-1 interacts specifically with 
the E74 binding site. 
To study the transcriptional capacity of Elf-1 and its deriv-
atives, an E74 binding site-driven luciferase reporter construct 
was used in transient transfection experiments. As a control 
we analyzed the ETS protein Elk-1 that is not active without 
mitogenic stimulation of cells [3]. In this functional assay, Elf-
1 as well as the Elfi-485 and Elfi-303 truncations were ap-
proximately 7-fold more active than Elk-1 (Fig. 4A). No acti-
vation of transcription was noticed with the tk80-luc reporter 
being devoid of E74 binding sites (Fig. 4A), demonstrating 
that Elf-1 acts site specifically. Further, a control gel retarda-
tion assay showed that comparable amounts of Elk-1 and the 
different Elf-1 constructs were produced in RK13 cells (Fig. 
4B). Deleting the first 85 amino acids decreased the transacti-
vation potential (see Elf86-619, Elf86-485 and Elf86-303 in 
Fig. 4A) confirming that amino acids 1-86 contain a trans-
activation domain. However, the residual activity of the N-
terminally deleted Elf-1 proteins implies that amino acids 86-
303, when bound to DNA via the ETS domain, might still 
slightly stimulate transcription. Please note that we could not 
test the impact of amino acids 206-265 on the activation 
potential with the E74 site-driven luciferase reporter, since 
these amino acids are part of the DNA binding domain and 
thus prohibit their deletion. Furthermore, in contrast to Elk-1, 
we could not find a significant increase of the activation po-
tential of Elf-1 after activation of MAPKs (Fig. 4C) or upon 
stimulation with phorbol esters (not shown), indicating that 
mitogenic signaling does not regulate Elf-1 function. 
4. Discussion 
Fig. 3. Interaction of Elf-1 with the E74 binding site. In vitro trans-
lated Elf-1 was employed in a gel retardation assay with the 32P-la-
beled E74-oligonucleotide. The specificity of binding activity was as-
sessed with different molar excesses of the indicated non-radioactive 
competitor oligonucleotides. 'X' denotes an unidentified complex 
not containing Elf-1. 
In this study, we have provided evidence that the transcrip-
tion factor Elf-1 is constitutively localized within the cell nu-
cleus. Since Elf-1, with a molecular weight of 68 kDa, is too 
big for a passive transport through the nuclear pores, active 
transport has to be involved in the nuclear localization of Elf-
1. The first 85 amino acids of Elf-1 are of no relevance for the 
intracellular localization; similarly, deleting C-terminal amino 
acids down to position 485 had no impact on the nuclear 
localization of Elf-1, and even Elfi-265, or E1Í86-265, was 
localized within the cell nucleus. This suggests that a nuclear 
localization signal is situated within amino acids 86-265. Sur-
prisingly, Elfi-303 was present in both the cytoplasm and the 
nucleus. This might be due to the fact that amino acids 266-
303, in the context of Elfi-303 but not in the context of full-
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Fig. 4. Elf-1 mediated Stimulation of E74 binding site-driven tran-
scription. A: Elf-1 transcriptional activity was studied in transient 
transfections of RK13 cells using an E74 binding site-driven lucifer-
ase reporter construct (E743-tk80-luc) or, as a control, the tk80-luc 
reporter. B: Whole-cell extracts of transiently transfected RK13 cells 
were employed in a gel retardation assay with 32P-labeled E74-oligo-
nucleotide. Asterisks mark the complexes containing the respective 
indicated protein. C: Transcriptional activation upon MAPK stimu-
lation. RK13 cells were cotransfected with p44 MAPK, an upstream 
activator of MAPK (constitutively active Raf-1 kinase [24]) and ei-
ther Elk-1 or Elf-1. 
length Elf-1 or Elfi-485, may mask a nuclear translocation 
signal within amino acids 86-265. 
A transactivation domain of Elf-1 was mapped to the N-
terminal 86 amino acids. Interestingly, deletion of amino acids 
206-619 resulted in an increase of the transactivation poten-
tial. Thus, the C-terminal amino acids may impede transacti-
vation by Elf-1. Specifically, amino acids 206-265 may be 
responsible for this intramolecular inhibition of transactiva-
tion, since deletion of amino acids downstream of position 
266 had no impact on the function of Gal4-Elf-1 fusions. 
However, our results were obtained with Gal4-fusion proteins 
which may blur the real situation. In this regard, it has been 
shown for Sap-la that the ETS domain, when not bound to 
DNA as in a Gal4-fusion at a Gal4 binding site-containing 
promoter, abrogates transcriptional activity of the Sap-la 
protein [26]. Here, we have similarly observed that the com-
plete deletion of the ETS domain in the G/E1-205 truncation 
is required for maximal transactivation, suggesting again that 
the ETS domain may negatively affect transactivation. 
The binding of Elf-1 to different promoters of lymphoid-
specific genes was described [13-17], but a direct impact of 
this factor for transcriptional activity of these promoters was 
not shown. Here, we demonstrate that Elf-1, when bound to 
the E74 target sequence, may stimulate transcription inde-
pendent of mitogenic signaling. These results are in agreement 
with two recent reports demonstrating that Elf-1 activates 
transcription of the immunoglobulin heavy-chain gene and 
the B-cell-specific protein kinase genes blk and lyn, the latter 
also being expressed in monocytes [21,22]. Therefore, Elf-1 
activity may be essential for the function of B-cells. In addi-
tion, Elf-1 may contribute to the regulation of the terminal 
deoxynudeotidyltransferase gene which is required during 
early B- and T-cell development [27]. However, since this 
gene is shut down in mature lymphocytes where Elf-1 is ex-
pressed [22], Elf-1 cannot be the sole regulator of the terminal 
deoxynudeotidyltransferase gene. Rather, as the analysis of 
lymphoid-specifically expressed genes such as IL-2 has often 
implicated multi-protein complexes in the regulation of gene 
activity, Elf-1 may be just one factor out of many that is 
required but not sufficient for the control of promoter activity. 
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